William Blair acted as a financial advisor to Inflexion Buyout V Investments LP (Inflexion), in connection with the successful close of a £2.3 billion multi-asset continuation fund, the Inflexion Continuation Fund I (the continuation fund). The continuation fund successfully closed in May 2025 and includes the following four assets:
- Aspen Pumps: A global manufacturer and distributor of condensate pumps, tools, and accessories.
- Rosemont Pharmaceuticals: One of the UK’s leading liquid pharmaceuticals businesses.
- Ocorian: A leading global fund, corporate and fiduciary services platform.
- CNX Therapeutics: A European speciality pharmaceutical platform dedicated to the supply of essential medicines.
About the Company
Inflexion is a leading European mid-market private equity firm which works in partnership with ambitious management teams of high growth, entrepreneurial businesses to accelerate sustainable growth. The firm’s flexible approach allows it to back both majority and minority investments, typically backing companies with an enterprise valuation ranging from €50 million to €1 billion. With bespoke teams and dedicated capital, Inflexion’s funds invest across a variety of sectors from offices in London, Manchester, Amsterdam, Stockholm, Frankfurt, and New York. The firm helps businesses achieve the next stage of growth through M&A, international expansion, digital enhancement, talent development, commercial strategy, sustainability focus, and access to Inflexion’s global network. Funds advised by Inflexion Private Equity Partners LLP have funds under management of about £11 billion.
Learn more about our private capital advisory and industrial growth products expertise.